Clinical Trials Arena on MSN3d
Trevi’s Phase IIb chronic cough success spikes stock by 71%The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Zacks Investment Research on MSN3d
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough StudyShares of Trevi Therapeutics TRVI surged 41% yesterday after it reported positive top-line data from the phase IIa RIVER ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Trevi Therapeutics, Inc. (NASDAQ:TRVI) reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) ...
Trevi Therapeutics (TRVI) surges 40% premarket as Haduvio proves effective in reducing chronic coughing in trials.
Trevi Therapeutics (TRVI) announced topline results from its Phase 2a RIVER trial of Haduvio for the treatment of patients with RCC. Haduvio ...
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) will likely be announcing its earnings results before the market opens on ...
The New Haven, Conn., biopharmaceutical company shared positive topline results from a Phase 2a trial of Haduvio for the treatment of patients with refractory chronic cough. Haduvio met the primary ...
Trevi Therapeutics (Nasdaq: TRVI) reported promising results from a mid-stage study of its experimental chronic cough ...
Shares of Trevi Therapeutics TRVI surged 41% yesterday after it reported positive top-line data from the phase IIa RIVER study evaluating its investigational therapy Haduvio as a potential ...
New Haven, Connecticut Tuesday, March 11, 2025, 18:00 Hrs [IST] ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback